1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Naturewise Biotech & Medicals Corporation

Naturewise Biotech & Medicals Corporation

TTPEX:4732
15.80
TWD
-0.20
(-1.25%)
831.03MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.46
1.58
1.16
1.32
1.59
2.57
7.15
5.47
4.45
4.07
3.25
4.55
3.63
- -
Basic EPS, GAAP
-0.45
-0.88
-0.67
-1.38
-1.39
-0.35
0.92
1.16
0.55
0.54
0.21
0.02
-1.89
- -
Free Cash Flow per Basic Share
-0.48
-0.63
-1.1
-1.53
-1.25
-0.44
0.27
0.97
0.6
0.24
1.25
-0.06
-2.32
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.08
0.26
0.5
0.2
- -
- -
Book Value per Share
7.18
9.86
9.19
7.81
6.42
6.08
9.5
10.67
11.13
11.44
11.29
13.19
12.94
11.5
Tangible Book Value per Share
7.01
9.65
8.97
7.54
4.94
4.68
8.49
9.73
10.28
10.68
10.63
12.63
12.39
11
Basic Weighted Avg Shares
27
30
43
43
43
42
43
56
56
56
49
49
49
48
Sales/Revenue/Turnover
65
48
50
58
69
108
307
307
250
229
160
224
177
- -
Operating Margin (%)
-28.86
-57.56
-87.64
-115.21
-86.76
-20.09
10.7
18.87
10.8
11.54
2.14
-5.37
-60.45
- -
Depreciation Expense
2
2
3
3
4
8
12
12
11
11
10
11
11
- -
Net Income, GAAP
-12
-26
-29
-60
-60
-15
40
65
31
30
10
1
-92
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
7.83
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-18.45
-55.38
-57.8
-104.31
-87.54
-13.66
12.91
21.28
12.33
13.13
6.32
0.4
-52.2
- -
Working Capital
179
395
363
302
195
183
460
525
555
579
573
720
578
496
LT Debt
- -
- -
- -
- -
- -
- -
3
- -
3
- -
3
- -
7
5
Total Equity
210
429
400
339
279
264
533
598
624
642
634
784
641
555
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
7.46
- -
- -
4.1
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
9.79
- -
- -
4.69
- -
- -
- -
- -
Return on Common Equity (%)
-5.58
-8.25
-7.04
-16.24
-19.56
-5.46
9.96
11.55
5.04
4.74
1.59
0.13
-13.52
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
6
6
27
LT Borrowings
- -
- -
- -
LT Finance Leases
2
7
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
1,099
1,001
831

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
720
638
577
Cash, Cash Equivalents & STI
578
470
409
Accounts Receivable, Net
15
26
19
Inventories
83
79
71
Total Current Liabilities
61
60
82
Payables & Accruals
- -
- -
- -
ST Debt
6
6
27
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.71%
2.26%
-18.22%
Free Cash Flow
405.23%
779.53%
3,750.34%
Net Income, GAAP
-1,087.27%
-2,120.11%
-10,387.74%
Sales/Revenue/Turnover
23.63%
-7.63%
-21.2%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
224
2025
- -
- -
177
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.02
2025
- -
- -
-1.89
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.2
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chung Yang Huang
Full Time Employees
32
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 36, Bade Road Taipei TP Taiwan 105
IPO Date
Dec 25, 2007
Website
naturewise.com.tw
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
NatureWise Biotech & Medicals Corporation specializes in creating advanced pharmaceutical compounds and health-focused products within Taiwan. The company's portfolio includes medications like LipoCol Forte, a specific capsule targeting high cholesterol and triglyceride levels, which was recognized as the initial traditional Chinese medicine by the Department of Health. Additionally, they develop NBM-BMX, an oral softgel for addressing certain cancers, with clinical trials underway for glioblastoma multiforme. Their health supplement offerings feature PPLs® Taiwanese Green Propolis, known for its immune-boosting, brain health, and memory-enhancing benefits, leveraging proprietary extraction methods for patented bioactive compounds. Established in 2000, the firm operates out of Taipei, Taiwan, emphasizing botanical and small molecule approaches.